-
公开(公告)号：US10034868B2
公开(公告)日：2018-07-31
申请号：US15523726
申请日：2014-11-04
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Inventor： Pierre-Louis Tharaux , Carole Henique Greciet , Guillaume Bollee
IPC: A61K31/4439
CPC classification number: A61K31/4439
Abstract: The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.
-
2.发明申请System and method for converting adiabatic RF pulses into pseudo adiabatic RF pulses 失效将绝热RF脉冲转换成伪绝热RF脉冲的系统和方法公开(公告)号：US20030234647A1
公开(公告)日：2003-12-25
申请号：US10441563
申请日：2003-05-20
Applicant: Corporation Du Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal (CHUM)
Inventor： Gilles Beaudoin , Jean-Charles Cote
IPC: G01V003/00
CPC classification number: G01R33/446
Abstract: Adiabatic RF pulses are very useful in MRI when precise flip angles are needed. Unfortunately, adiabatic pulses suffer from a long application time and a high SAR. A new concept to modify the usual adiabatic pulse into a nullpseudo-adiabaticnull pulse having a shorter application time and lower SAR is introduced. For example, a BIR-4 of 32 ms of application time and a relative SAR of 20 will be transformed into a BIR-4-S1 of 1 ms and relative SAR of 1. The new pulse obtained stays insensitive for a large B1 range but loses its slice selectivity to become a 3D pulse. Experimental results are presented to illustrate the sensitivity to B1 and B0.
Abstract translation: 当需要精确翻转角时，绝热RF脉冲在MRI中非常有用。 不幸的是，绝热脉冲具有长的施加时间和高的SAR。 引入了将常规绝热脉冲修改为具有较短施加时间和较低SAR的“假绝热”脉冲的新概念。 例如，32毫秒应用时间的BIR-4和20的相对SAR将被转换成1毫秒的BIR-4-S1和1的相对SAR。所获得的新脉冲对于大的B1范围而言不敏感，但是 失去其切片选择性，成为3D脉冲。 提出了实验结果，以说明对B1和B0的敏感性。
-
Patent Agency Ranking
3.发明申请公开(公告)号：US20180036297A1
公开(公告)日：2018-02-08
申请号：US15523726
申请日：2014-11-04
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Inventor： Pierre-Louis THARAUX , Carole HENIQUE GRECIET , Guillaume BOLLEE
IPC: A61K31/4439
CPC classification number: A61K31/4439
Abstract: The present invention relates to the prevention and the treatment of rapidly progressive glomerulonephritis.
-
公开(公告)号：US08915852B2
公开(公告)日：2014-12-23
申请号：US13936689
申请日：2013-07-08
Inventor： Emilie Franceschini , Guy Cloutier
CPC classification number: G01S15/02 , A61B5/14535 , A61B8/0833 , A61B8/5223 , G01S7/52036
Abstract: A method for characterizing ultrasound scatterers in a medium comprises receiving ultrasound data representing a region of interest comprising a plurality of scatterers in a medium, the plurality of scatterers including aggregates of the scatterers. The ultrasound data is modeled data using an effective medium theory combined with the structure factor model, the structure factor model defining the spatial organization and concentration of the aggregates. The modeled ultrasound data is compared to theoretical data obtained with the effective medium theory combined with the structure factor model. From the comparison, dimensional data of the aggregates of the scatterers and the volume concentration of scatterers in the medium is determined.
Abstract translation: 用于表征介质中的超声波散射体的方法包括：接收表示包括介质中的多个散射体的感兴趣区域的超声波数据，所述多个散射体包括散射体的聚集体。 超声数据是使用有效介质理论结合结构因子模型，结构因子模型定义聚集体的空间组织和浓度的建模数据。 将建模的超声数据与使用有效介质理论结合结构因子模型获得的理论数据进行比较。 通过比较，确定了散射体的聚集体和培养基中散射体的体积浓度的尺寸数据。
-
公开(公告)号：US20240285790A1
公开(公告)日：2024-08-29
申请号：US18565379
申请日：2022-06-10
Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. , CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Inventor： Marzena PAZGIER , William D. TOLBERT , Dung N. NGUYEN , Andres FINZI , Jonathan RICHARD
CPC classification number: A61K47/6841 , A61K45/06 , A61K47/6811 , A61K47/6889 , A61P31/18
Abstract: The present disclosure provides for antibody conjugate molecules (Ab-CD4 conjugates) comprising an antibody, at least one linker, and at least one CD4 compound, wherein the at least one linker links the antibody to the at least one CD4 compound and wherein the Ab-CD4 conjugate is capable of neutralizing an HIV virus, as well as methods of killing HIV-infected cells through an Fc-mediated effector function using the Ab-CD4 conjugates. Also provided are pharmaceutical compositions comprising the Ab-CD4 conjugates and methods of treating or preventing HIV injection in a subject.
-
6.发明申请SYNGAP1 DYSFUNCTIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR MENTAL RETARDATION 审中-公开SYNGAP1功能及其在诊断和治疗应用中的应用精神滞后公开(公告)号：US20130065238A1
公开(公告)日：2013-03-14
申请号：US13673034
申请日：2012-11-09
Applicant: Centre Hospitalier Universitaire Sainte-Justine , Centre Hospitalier De L'Universite De Montreal
Inventor： Jacques MICHAUD , Fadi HAMDAN , Guy ROULEAU , Julie GAUTHIER
CPC classification number: C07K14/4706 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , G01N33/6896 , G01N2500/04 , G01N2800/2814
Abstract: The invention identifies Syngap1 dysfunctions as causative of mental retardation. Described are methods of detecting mental retardation and methods of detecting non-syndromic mental retardation (NSMR) in a human subject. Particular methods comprise sequencing a human subject's genomic DNA for comparison with a control sequence from an unaffected individual. Also described are probes, kits, antibodies and isolated mutated Syngap1 proteins.
Abstract translation: 本发明鉴定了Syngap1功能障碍是智力迟钝的原因。 描述了检测精神发育迟滞的方法和检测人类受试者中非综合征性精神发育迟滞（NSMR）的方法。 特定的方法包括测序人受试者的基因组DNA以与来自未受影响个体的对照序列进行比较。 还描述了探针，试剂盒，抗体和分离的突变的Syngap1蛋白。
-
公开(公告)号：US20240360510A1
公开(公告)日：2024-10-31
申请号：US18563450
申请日：2022-05-24
Applicant: UNIVERSITE PARIS-SACLAY , INSERM (Institut National de la Santé et de la Recherche Médicale) , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Inventor： Jérôme BOULIGAND , Isabelle Bourdeau , Fanny CHASSELOUP , André Lacroix , Peter KAMENICKÝ
IPC: C12Q1/6883 , A61K45/00 , G01N33/68
CPC classification number: C12Q1/6883 , A61K45/00 , G01N33/6893 , C12Q2600/156 , G01N2333/90274 , G01N2800/04 , G01N2800/50
Abstract: The present results show that KDM1A is a key epigenetic regulator of tissue-specific expression of GIP receptor and possibly of other receptors from the G-protein coupled receptor family in hormone-producing glands, and that its alteration leads to the development of aberrant overexpression of eutopic hormone receptors or expression of ectopic hormone receptors that lead to abnormal steroidogenesis. They also show that loss of expression of KDM1A is likely to be the initiating event that trigger the abnormal cell proliferation leading to the development of tissue lesions in adrenal and possibly in other endocrine tissues (notably in the adrenal glands). The present invention therefore proposes to detect altered expression of KDM1A in the genome of subjects, in order to diagnose a genetic predisposition to an endocrine disease and/or to an endocrine hyperplasia. On another hand, the present results suggest that the physiological eutopic GIP receptor expression in the pancreas may be also epigenetically regulated by KDM1A. This expression could be pharmacologically targeted by KDM1A inhibitors so as to treat patients suffering from diabetes mellitus and other metabolic diseases.
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
